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Chen et al., 2002a, 2002b; Gharib et al., 2002; Jones et al.,
2002; Meehan et al., 2002) and fluids (Petricoin et al., 2002a,
2002b), as the ultimate aim of translational research is to bring
basic discoveries closer to the bedside (Celis, 2002; Petricoin et
al., 2002c). The implementation of discovery-driven translation-
al research will not only require coordination of basic research
activities, facilities, and infrastructures, but also the creation of
an integrated and multidisciplinary environment with the partici-
pation of a dedicated team of clinicians, oncologists, patholo-
gists, and epidemiologists, as well as industrial partners. Issues
related to sample collection, handling, and storage, number of
patients, availability of normal controls, tissue banks, quality of
the clinical information, follow-up studies, and ethical considera-
tions are critical, and must be carefully considered. As we rede-
fine the manner in which we approach cancer, changes also
need to be made in the way cancer research is funded.
Translational cancer research has only recently gathered
momentum among the proteomic research community, and as a
result there are just a few long-term programs that have been
initiated using tissue biopsies and biological fluids. A recent
example of what has been achieved so far using fluids is illus-
trated by the work of Petricoin, Liotta, and coworkers, who have
used a combination of mass spectra generated by surface-
enhanced laser desorption ionization time-of-flight (SELDI-
TOF) and artificial intelligence-based informatic algorithms to
search for protein patterns or features in serum that detect ovar-
ian and prostate cancer (Petricoin et al., 2002a, 2002b). These
studies, which have been recently reviewed by Daly and Ozols
(2002) in this journal, require further validation using a larger
sample number, but have clearly illustrated the clinical potential
of the chip technology in the diagnosis of some cancers.
Analysis of tissue biopsies is by far more complicated than
the analysis of fluids, due to the heterogeneous nature of the
samples. Today, two-dimensional polyacrylamide gel elec-
trophoresis (2D PAGE) (O’Farrell, 1975), often referred as gel-
based proteomics, multidimensional chromatography, and
protein biochips, in combination with mass spectrometry
(McDonald and Yates, 2002; Yip and Lomas, 2002; Wu and
McCoss, 2002, and references therein), are among the pro-
teomic tools that are available for biomarker and drug target dis-
covery. Considerable work is currently underway to explore
applications of non-gel-based proteomics in various areas of
biology, as this technology has much to offer. What follows
below is a short description of the gel-based technology as
applied to whole fresh tissue specimens in the context of trans-
Introduction
The sequencing of the human and other important genomes is
only the beginning of the quest to understand the functionality of
cells, tissues, and organs, both in health and disease. Together
with advances in bioinformatics, this development has paved
the way to the revolution in biology and medicine that we are
experiencing today.We are rapidly moving from the study of sin-
gle molecules to the analysis of complex biological systems,
and the current explosion of emerging technologies within pro-
teomics and functional genomics promises to elicit major
advances in medicine in the near future.
Cancer, being a complex disease that affects a significant
fraction of the population, is foreseen as a prime target for the
new technologies, as tools for the high throughput analysis of
genes and proteins might expedite the applications of basic
research findings into daily clinical practice through translational
research. In particular, proteomic technologies are expected to
play a key role in the study and treatment of cancer, as they pro-
vide invaluable resources to define and characterize regulatory
and functional networks, to investigate the precise molecular
defect in diseased tissues and biological fluids, and for develop-
ing specific reagents to precisely pinpoint a particular disease or
stage of a disease. For drug discovery, proteomics assist with
powerful tools for identifying new clinically relevant drug targets,
and provide functional insight for drug development.
Proteomics encompasses many platform technologies for
protein separation and identification, for determining their bio-
molecular interactions, function, and regulation, and for anno-
tating, storing, and distributing protein information (Figure 1)
(Celis et al., 1998; Aebersold and Goodlett, 2001; Chakravarti et
al., 2002; Figeys, 2002; Gavin et al., 2002; Liu et al., 2002;
Mylvaganam et al., 2002; Panisko et al., 2002; Yanagida, 2002,
and references therein). The proteome is much more complex
and dynamic than the genome, and the task of deciphering it
even in a single cell type is daunting, as there may be many
thousands of proteins, including splice variants, posttranslation-
al modifications, and cleavage products, present in a cell at any
given time. Moreover, the dynamic range of protein expression
expands over several orders of magnitude, a fact that limits their
characterization and analysis.
Today, the application of novel technologies from pro-
teomics to the study of cancer is slowly shifting to the analysis
of clinically relevant samples such as biopsy specimens (Celis
et al., 1996a, 1999a, 1999b, 2002; Alaiya et al., 2000, 2002;
Lawrie et al., 2001; Wulfkuhle et al., 2001; Ahram et al., 2002;
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Proteomics provides powerful tools for the study of clinically relevant samples in the context of translational cancer research.
Here we briefly review applications of gel-based proteomics for the study of bladder and lung cancer using fresh tissue biop-
sies. In general, these studies have emphasized the potential of the technology for biomarker discovery, as well as for
addressing the issue of cancer heterogeneity.
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lational research. We also provide selected examples of what
has been accomplished in bladder and lung cancer, two of the
most comprehensively studied malignancies using 2D gels in
combination with other technologies.
Gel-based proteomics: A platform technology for the
analysis of tissue biopsies
2D PAGE separates proteins based on their molecular masses
and isoelectric points (pIs), and is the method of choice to ana-
lyze complex tissue samples that are often composed of differ-
ent cell types (Celis et al., 1996a). For many years, the 2D
PAGE technology relied on the use of carrier ampholytes to
establish the pH gradient, but this technique suffers from lack of
reproducibility due to variations in the batches of ampholytes
used to generate the pH gradients. Lately, however, with the
introduction of immobilized pH gradients (IPGs) (Görg et al.,
2000, and references therein), which are an integral part of the
polyacrylamide matrix, it has been possible to obtain more
reproducible focusing patterns. IPGs avoid some of the prob-
lems associated with carrier ampholytes, such as cationic drift,
allow a higher loading capacity for micropreparative runs, and
provide increased resolution when narrow pH gradients are
used (approximately 0.05 pH/cm; zoom gels). Critical issues in
gel-based proteomics relate mainly to sample preparation and
standardization of the gel running conditions (Celis and
Gromov, 1999).
For 2D PAGE-based protein profiling, one usually chooses
a condition of interest and lets the cells or tissue reveal the
global protein response, as all detected proteins can be ana-
lyzed quantitatively with respect to each other. Figure 2 shows
2D gel isoelectrofocusing (IEF) autoradiograms of proteins
from fresh biopsies obtained from normal urothelium (transi-
tional epithelium) and an invasive transitional cell carcinoma
(TCC, Gr. III, T2-4) metabolically labeled with [35S]-methionine.
Interpretation of the expression patterns of tissues demands
prior knowledge of specific protein markers for the individual
cell types contributing to the overall picture, a fact that requires
considerable investment in time at the onset of the project
(Celis et al., 1996a). Alternatively, selected groups of cells can
be recovered from hematoxylin or immunostained tissue sec-
tions using microdissection procedures (Emmert-Buck et al.,
1996). The number of cells required for gel analysis, however,
is in the order of 50,000 cells.
Protein profiles can be scanned and quantitated to search
for changes in the levels of preexisting proteins, induction of
new products, and groups of coregulated polypeptides, and
interesting targets or molecular signatures can be identified
using mass spectrometry (Aebersold and Goodlett, 2001, and
references therein) and immunoblotting (Celis et al., 1995), pro-
vided that specific antibodies are available. The latter will reveal
posttranslational modified variants as well as spliced variants
that may be difficult to identify using a combination of 2D PAGE
and mass spectrometry. Antibodies are invaluable to validate
protein expression data (levels as well as cell type involved)
using immunohistochemistry on frozen or paraffin sections
(Figure 2).
Protein expression data gathered by 2D PAGE in combina-
tion with other technologies can be stored in comprehensive
databases that document protein expression in normal and tumor
tissues, as exemplified by the TCC (http://proteomics.cancer.dk)
(Figure 3) and lung proteomic databases (Oh et al., 2001). The
TCC database is available online and is updated regularly. By
clicking on a spot, one can readily retrieve information on any pro-
tein, known or unknown. Files for known proteins have links to
other databases available online. As these databases achieve a
critical mass of data, they will become valuable resources of infor-
mation for expediting the identification of signaling pathways and
components that are affected in various types of cancers. In addi-
tion, they are expected to facilitate the identification and validation
of targets with a proven role in the disease.
As we stand today, one could expect to visualize a maxi-
mum of about 4,000 to 5,000 cellular and secreted proteins with
the gel-based technology using [35S]-methionine labeled whole
tissue samples. This fraction is still short of the total number of
polypeptides that may be present in a given cell type, but still
sufficient to start biomarker discovery. Missing polypeptides are
either not resolved by the pH gradient (too basic or too acidic),
or do not enter the gel due to solubilization problems (mem-
brane proteins) or molecular weight size, or simply because
they are not detected due to limitations in the sensitivity of the
current procedures, which are based mainly on isotope incorpo-
ration (autoradiography, fluorography) and staining with silver
nitrate or fluorescent dyes (Patton, 2002, and references there-
in). Some of these limitations can be partly overcome by apply-
ing extensive prefractionation procedures to enrich for the
desired protein, protein fraction, or subcellular component.
Applications of gel-based proteomics to the study of cancer
Even though there are only a few large cancer proteomic pro-
jects that are well underway at the moment, such as the bladder
and lung programs (see below), there is evidence in the litera-
ture indicating that the gel-based technology can be applied to
the analysis of a variety of tumor types that include breast
(Franzen et al., 1996; Wulfkuhle et al., 2001), colon (Stulik et al.,
2001; Lawrie et al., 2001; J.E.C., unpublished data), prostate
(Ahram et al., 2002; Meehan et al., 2002; Alaiya et al., 2000),
ovary (Jones et al., 2002; Alaiya et al., 2002), and kidney (J.E.C.
and H. von der Maasse, unpublished observations). Moreover,
there have been several reports on leukemia and hematological
malignancies (Melhem et al., 1997). Applications to bladder and
lung cancer, two of the most comprehensively studied malig-
nancies using the gel-based technology in the context of trans-
lational research, are briefly reviewed below.
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Figure 1. Technologies and resources in proteomics
Proteomics encompasses many platform technologies for protein separa-
tion and identification, for determining their biomolecular interactions,
structure, function, and regulation, and for annotating, storing, and distrib-
uting protein information. In the context of translational cancer research,
proteomics requires well-established tissue banks as well as tools from
genomics and transcriptomics.
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Bladder cancer
Bladder cancer comprises a broad spectrum of tumors with vari-
ous histological types that include TCCs, adenocarcinomas, and
squamous cell carcinomas (SCCs) (Friedell et al., 1983). TCCs
are by far the more prevalent tumors and represent nearly 95%
of all bladder cancers in the Western Hemisphere. SCCs, on the
other hand, encompass a small percentage (2%–3%) of all blad-
der lesions diagnosed in Europe and America, but are very fre-
quent (80%) in areas of Africa and the Middle East, where
Schistosoma haematobium, a parasite that induces bladder
SCCs in humans, is prevalent (El-Bolkainy, 1983).
For several years, our group has collaborated with clinicians
to explore the possibility of using proteome expression profiles of
bladder tumors as fingerprints to objectively subclassify
histopathological types, and as a staring point for searching for
protein markers that may form the basis for diagnosis, prognosis,
and treatment. These studies have been complemented with
cDNA array analysis (Celis et al., 2000), and by genome-wide
studies of gene copy numbers, transcripts, and protein levels in
pairs of noninvasive and invasive TCCs (Ørntoft et al., 2002).
More than 1000 fresh specimens that include tumors, nor-
mal biopsies, and cystectomies have been systematically
analyzed so far using 2D PAGE, and we have established
protein expression databases of TCCs and SCCs, as well as
other cell types that are available through the Internet
(http://proteomics.cancer.dk) (Figure 3). So far, these studies
have revealed several protein markers for TCC progression
(Celis et al., 1996a) and a marker, psoriasin, that is produced
specifically by SCCs and that is externalized to the urine (Celis
et al., 1996b). In addition, this work has led to the development
of novel strategies for the identification of tumor heterogeneity
among low-grade papillary TCCs (Celis et al., 2002) as well as
early metaplastic lesions in SCC-bearing patients (Celis et al.,
1999a; see below).
Proteomic strategies to identify tumor heterogeneity
among low-grade papillary TCCs
Papillary TCCs are typically superficial at first presentation and
are often multifocal. These tumors exhibit a high frequency of
recurrence (>60%), and 10%–15% of them will progress to life-
threatening malignancies over a long period of time (Cheng et
al., 2000). Presently, it is not possible to assess with certainty
the biological behavior of these tumors based on clinical or mor-
phological criteria alone, and as a result it is important to identi-
fy tumor subtypes that will develop recurrences and/or progress
to invasive disease. Moreover, it is vital to distinguish those
lesions that have no significant effect on the life expectancy of
the patient, as all tumor-bearing patients are diagnosed with
cancer, a fact that has practical and economic implications as
well as a profound psychological effect on the patient.
The strategy for identifying cancer heterogeneity among
low-grade papillary TCCs encompasses a blind and systematic
study of the proteome expression profiles of fresh biopsy speci-
mens from both normal and tumor origin (Celis et al., 2002).
Large numbers of samples are required to define a baseline of
normal and abnormal protein expression (Celis et al., 1996a,
2002). First, one identifies major proteins that are differentially
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Figure 2. Highly deregulated proteins in invasive TCCs
[35S]-methionine-labeled proteins synthesized by normal urothelium and an invasive TCC (Grade III, T2-4) were separated by 2D PAGE (IEF) and visualized by
autoradiography. Proteins indicated with red are upregulated in the tumor, while those indicated in green are downregulated. The position of actin is indi-
cated for reference.
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expressed in invasive lesions (Gr III, T2-4) as compared to nor-
mal urothelium (Figure 2, only a few highly deregulated proteins
are indicated), and thereafter uses specific antibodies against
these proteins to immunostain cryostat sections of low-grade
papillary tumors diagnosed as having the same grade of atypia
and stage (Gr I, Ta) by the pathologist. The rate-limiting step in
the procedure lies in the preparation of specific antibodies that
will work both in immunoblotting as well as in immunofluores-
cence. So far, these studies have identified several types of can-
cer heterogeneity (Celis et al., 2002) that affect either the basal
proliferative compartment (Figures 4Aa and 4Ab), the umbrella
cells (Figure 4Ac), or the suprabasal layers (not shown). Control
staining of normal urothelium with these antibodies is shown in
Figures 4Ad–4Af. Analysis of the clinical data gathered through
a period of five years indicated that lesions displaying phenotyp-
ic alterations in the basal, proliferative compartment (Figures
4Aa and 4Ab) showed the highest number of recurrences. Even
though a long-term prospective study involving a larger sample
size with regular follow-up is required to assess the biological
potential of these lesions, the data clearly illustrate the potential
of combining proteomics with immunohistochemistry to reveal
cancer heterogeneity and to correlate it with outcome.
Identification of early metaplastic lesions in SCC-bearing
patients
An important task in cancer control and prevention is the detec-
tion of the disease at an early stage to allow rapid intervention
and treatment. SCCs of the bladder are highly malignant and
have a bad prognosis, and the success of treatment relies heav-
ily on early detection.Thus, the identification of early precancer-
ous lesions as well as markers in the urine may prove to be
instrumental in the treatment of the disease.
To search for precancerous lesions, we have pursued a sys-
tematic analysis of the proteome expression profiles of fresh
tumors as well as urothelial tissue from patients that have
undergone removal of the bladder due to
invasive disease (cystectomy) (Celis et
al., 1999a). Since bladder cancer is a
field disease, that is, a large part of the
urothelium is at risk of developing the
disease, we surmised that cystectomy
specimens might exhibit a spectrum of
abnormalities ranging from early meta-
plastic stages to invasive disease. First,
we identify proteins that are differentially
expressed by pure SCCs and normal
urothelium, and thereafter we use
antibodies against these putative mark-
ers to stain serial cryostat sections
(immunowalking) obtained from bladder
cystectomies of SCC-bearing patients.
Indeed, these studies have revealed sev-
eral types of metaplastic lesions that can
be differentiated based on the staining with antibodies against
keratin 19 (expressed by normal urothelium, Figure 4Bg), 14
(expressed by pure SCCs, Figure 4Be), and other markers
identified by the gel analysis (Celis et al., 1999a). Figures
4Ba–4Bc depict a series of 3 cryostat sections from a region
close to the tumor showing transition from “normal” urothelium
to a keratin 19 negative metaplastic type lesion that is located at
the right side of the section (Figure 4Ba). This particular lesion
closely resembles the tumor phenotype, as it stains with keratin
14 antibodies (Figure 4Bb; compare with Figure 4Be), and the
basal cells do not express keratin 13 (Figure 4Bc), a protein not
expressed by the tumor (Figure 4Bf). It is possible that this par-
ticular tumor arose from the expansion of the basal cell com-
partment of this type of lesion. As additional antibodies become
available against specific markers, we will be able to accurately
define the phenotype of precancerous lesions. Specific mem-
brane markers, or secreted proteins derived from these lesions
(Celis et al., 1996b), may provide with potential biomarkers for
early diagnosis using urine samples.
Lung cancer
Lung cancer is the most common cause of cancer death in
women and men and is a major public health concern in the
Western world. Hanash and colleagues have analyzed over
1000 lung cancer-related samples using 2D PAGE in combina-
tion with mass spectrometry, and have constructed the lung pro-
teomic database (Oh et al., 2001) that integrates protein and
gene expression data at the RNA level. The aim of their studies
is to identify biomarkers for the early detection of cancer, for
developing novel classification of tumors, and for revealing
novel targets for therapeutic intervention (Hanash et al., 2001;
Chen et al., 2002a; Gharib et al., 2002).
The parallel transcriptomic and proteomic analysis of lung
tumors has permitted this group to compare mRNA and protein
P R I M E R
Figure 3. Master synthetic image of human blad-
der TCC proteins separated by IEF 2D PAGE as
depicted online (http://proteomics.cancer.dk)
Proteins labeled with a cross correspond to
known proteins. By clicking on any spot, it is pos-
sible to open a file that contains protein infor-
mation available in the database as well as links
to other related websites. Only part of the file for
A-FABP is shown.
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levels in the same tumors (Chen et al., 2002b). The integrated
intensities of 165 protein spots representing protein products of
98 genes were analyzed in 76 lung adenocarcinomas and 9
unaffected lung tissues using 2D PAGE. For the same 85 sam-
ples, mRNA levels were determined using oligonucleotide
microarrays. Only 21 out of the 98 genes analyzed (21.4%)
showed a statistically significant correlation between protein
and mRNA levels (r > 0.2445; p < 0.05). The mRNA/protein cor-
relation coefficients also varied between isoforms of the same
protein, suggesting that isoform-specific mechanisms may be
involved in regulating protein abundance. Recently, the group
identified a battery of genes (Beer et al., 2002) and proteins,
which included specific cytokeratin isoforms that are predictive
of survival in lung cancer (Gharib et al., 2002).
Hanash and colleagues have also searched for circulating
tumor antigens by screening for autoantibodies in lung cancer
patients using Western blotting (Brichory et al., 2001a). Briefly,
2D gel blots of the lung adenocarcinoma cell line A549 have
been incubated with sera from patients with lung adenocarcino-
mas, other cancers, and noncancer controls. These studies
have revealed autoantibodies against glycosylated annexins I
and II in 60% of the patients with lung adenocarcinomas and
33% of patients with SCCs. Similarly, studies involving sera
from 64 newly diagnosed patients with lung cancer, 99 patients
with other types of cancer, and 71 noncancer controls revealed
a tumor antigen, protein gene product 9.5 (PGP 9.5, a
neurospecific protein), that induces a
humoral response in lung cancer
(Brichory et al., 2001b).
In an effort to speed up the analysis
of serum for autoantibodies to lungs
bearing antigens, Madoz-Gurpide et al.
(2001) have developed a novel approach
that combines liquid phase protein sepa-
rations with microarray technologies.
Whole cell or tissue lysates are fraction-
ated by isoelectric focusing and reverse
phase chromatography into hundreds of
fractions, which are then arrayed onto
nitrocellulose-coated slides and incubat-
ed with the sera. Such biochips require
low sample volume and provide a rapid
procedure to molecularly profile the antibody response to tumor
antigens in cancer.
Perspectives
Today it is becoming increasingly clear that translational cancer
research must make use of the entire armamentarium of tech-
nology and resources available within proteomics, genomics,
and functional genomics (Figure 1). No single laboratory or
research institution has the critical mass or the resources to
tackle such a complex biological problem, and as a result, it is
essential to join forces in order to make an impact on the dis-
ease.With this goal in mind, the Danish Cancer Society recently
supported the establishment of the Danish Centre for
Translational Research in Breast Cancer (DCTB), a network
that brings together basic scientists working in various areas of
cancer research (cell cycle, metastasis, apoptosis, signaling
pathways), with clinicians, oncologists, surgeons, pathologists,
and epidemiologists, in an integrated environment for the study
of one of the most common malignancies and causes of cancer
death in women worldwide. Briefly, the strategy is based on the
analysis of fresh tissue biopsies (normal and cancer) obtained
from the same patient using an array of state-of-the-art tech-
nologies from genomics, transcriptomics, proteomics, and func-
tional genomics. Small tissue samples dissected from the same
tumor or normal tissue are distributed to members of the Centre
who apply various experimental paradigms and share their data
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Figure 4. Tumor and tissue heterogeneity in
bladder cancer
A: Cancer heterogeneity among low-grade
papillary TCC (GrI, Ta).
a–c show cancer heterogeneity as revealed by
staining cryostat tumor sections with antibodies
against keratins 5, 20, and 8, respectively. d–f
show control staining of normal urothelium with
these antibodies. From Celis et al. (2002); repro-
duced by permission from Molecular Cell
Proteomics.
B: Identification of metaplastic lesions in SCC
cystectomy 884-1. Serial cryostat sections were
reacted with antibodies against proteins
differentially expressed by normal urothelium
(g–i) and the corresponding SCC (d–f). a–c
show 3 serial sections reacted with antibodies
against keratins 19, 14, and 13, respectively
(immunowalking). White arrows indicate refer-
ence points for comparison. From Celis et al.
(1999a); reproduced by permission from
Cancer Research.
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via databases that will be linked with clinical information to gen-
erate a prognostic index and molecular profile for each patient.
The aim of the program is to elucidate the biochemical path-
ways affected, to develop noninvasive diagnostics able to detect
cancer in the very early stages, to develop and/or improve
methodologies to determine the various stages of breast cancer
and to predict outcome, and to apply molecular classification to
identify the best responders to therapy. Biomarkers of interest
might be tested using the Danish Breast Cancer Group (DCBG)
tumor repository bank, which contains tissue samples from
about 10,000 breast cancer patients with a full clinical follow-up.
These studies will be complemented by the analysis of serum
samples as well as nipple fluid aspirate. Altogether, these capa-
bilities are expected to accelerate drug development and
improve clinical trial methodologies. The immediate outcome of
these investigations will manifest as enhanced patient survival
and improved quality of life.
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